Radiofrequency Ablation in Management of Liver Metastase From Breast Cancer
Radiofrequency Ablation in Management of Liver Metastase From Breast Cancer
Objective. Systemic chemotherapy remains the standard treatment for patients with breast cancer hepatic metastases. Resection of metastases has survival advantages in a small percentage of selected patients. Radiofrequency ablation has been used in small numbers of selected patients. This small series was undertaken to review our experience with radiofrequency ablation in the management of patients with breast cancer hepatic metastases.
Conclusion. Radiofrequency ablation of breast cancer hepatic metastases is safe and may be used to control hepatic deposits in patients with stable or no extrahepatic disease.
The liver is an uncommon site for isolated solitary breast cancer metastases, reported to occur in approximately 39% of breast cancer patients. In the setting of disseminated metastatic breast disease, hepatic metastases have been identified in as many as 5575% of patients at autopsy, and hepatic failure is a recognized major cause of death, occurring in up to 20% in this population.
Although chemotherapy has historically been the main treatment for patients with metastatic breast cancer, response rates have been low in patients with disseminated breast metastases that involved the liver. In recent small series of selected patients with hepatic metastases, regional chemotherapy with metastasectomy and metastasectomy with systemic chemotherapy had a survival advantage when compared with chemotherapy regimens alone. In a subset of this population, radiofrequency ablation was performed before resection. Radiofrequency ablation and its benefits in selected patients with liver metastases from malignancies such as colorectal cancer have been reported.
Prior clinical series of radiofrequency ablation in the management of breast hepatic metastasis reported the results in 24 and 14 patients, respectively, most of whom had metastatic disease confined to the liver. A recent series of radiofrequency ablation for the management of hepatic metastases from breast cancer included 11 of 19 patients with stable extrahepatic disease, showing success in hepatic disease control and survival, particularly in patients with disease confined to the liver. Our series describes the results of radiofrequency ablation in the management of breast cancer metastases to the liver in a selected population with a significantly larger proportion (10/12) of extrahepatic metastatic load at the time of the radiofrequency ablation.
Objective. Systemic chemotherapy remains the standard treatment for patients with breast cancer hepatic metastases. Resection of metastases has survival advantages in a small percentage of selected patients. Radiofrequency ablation has been used in small numbers of selected patients. This small series was undertaken to review our experience with radiofrequency ablation in the management of patients with breast cancer hepatic metastases.
Conclusion. Radiofrequency ablation of breast cancer hepatic metastases is safe and may be used to control hepatic deposits in patients with stable or no extrahepatic disease.
The liver is an uncommon site for isolated solitary breast cancer metastases, reported to occur in approximately 39% of breast cancer patients. In the setting of disseminated metastatic breast disease, hepatic metastases have been identified in as many as 5575% of patients at autopsy, and hepatic failure is a recognized major cause of death, occurring in up to 20% in this population.
Although chemotherapy has historically been the main treatment for patients with metastatic breast cancer, response rates have been low in patients with disseminated breast metastases that involved the liver. In recent small series of selected patients with hepatic metastases, regional chemotherapy with metastasectomy and metastasectomy with systemic chemotherapy had a survival advantage when compared with chemotherapy regimens alone. In a subset of this population, radiofrequency ablation was performed before resection. Radiofrequency ablation and its benefits in selected patients with liver metastases from malignancies such as colorectal cancer have been reported.
Prior clinical series of radiofrequency ablation in the management of breast hepatic metastasis reported the results in 24 and 14 patients, respectively, most of whom had metastatic disease confined to the liver. A recent series of radiofrequency ablation for the management of hepatic metastases from breast cancer included 11 of 19 patients with stable extrahepatic disease, showing success in hepatic disease control and survival, particularly in patients with disease confined to the liver. Our series describes the results of radiofrequency ablation in the management of breast cancer metastases to the liver in a selected population with a significantly larger proportion (10/12) of extrahepatic metastatic load at the time of the radiofrequency ablation.
Source...